Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows an Over 50% Decrease in Opioid Self-Administration in a Predictive Rodent Model

— BMB compound significantly reduced fentanyl intake in an animal model of opioid abuse — — Potential to reduce continued opioid use in humans, a key treatment goal for opioid use disorder — — A brief virtual presentation discussing the findings is scheduled for Monday, March 15 th at 11am ET — VANCOUVER, British Columbia, March 15, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,”…

Source